Cardiovascular diseases are the leading cause of mortality in men and women. Unfortunately, women have traditionally been excluded from clinical trials, and female animals have been used less or sex was not reported in basic research studies. Until recently, consideration of both sexes was not required in clinical and preclinical studies focusing on cardiovascular diseases. However, the number of clinical and experimental papers dealing with sex differences and heart disease significantly increases during the last years. This trend is obviously the result of at least two facts: the number of examples of different behavior of the male and female heart under physiological and pathological conditions is steadily increasing and there were controversial reports on the beneficial and adverse effect of hormonal replacement therapy. Detailed molecular and cellular mechanisms of these differences are still unknown but one is clear already today: sex differences are so important that they should be considered by the selection of optimum diagnostic and therapeutic procedures in clinical practice. The book presents 16 manuscripts on sex differences of heart disease, as developed by several investigators; the volume is organized in four parts. Part I, dealing with sex differences in cardiac ischemic injury, includes 5 chapters on experimental aspects of cardiac ischemia/reperfusion injury, the role of testosterone, and clinical aspects of ischemic heart disease. Part II is devoted to sex differences in heart failure and includes four chapters. Discussion in this part of the book is centered around the sex differences in heart failure due to volume overload. Part III of this volume includes four papers on risk factors of cardiovascular diseases, namely hypertension and obesity, and, finally, three chapters in part IV deal with sex differences of cardiac mitochondria under different pathological conditions. We believe this book will be very useful for cardiovascular scientists, graduate students, postdoctoral fellows and other health professionals.

It's obvious why only men develop prostate cancer and why only women get ovarian cancer. But it is not obvious why women are more likely to recover language ability after a stroke than men or why women are more apt to develop autoimmune diseases such as lupus. Sex differences in health throughout the lifespan have been documented. Exploring the Biological Contributions to Human Health begins to snap the pieces of the puzzle into place so that this knowledge can be used to improve health for both sexes. From behavior and cognition to metabolism and response to chemicals and infectious organisms, this book explores the health impact of sex (being male or female, according to reproductive organs and chromosomes) and gender (one's sense of self as male or female in society). Exploring the Biological Contributions to Human Health discusses basic biochemical differences in the cells of males and females and health variability between the sexes from conception throughout life. The book identifies key research needs and opportunities and addresses barriers to research. Exploring the Biological Contributions to Human Health will be important to health policy makers, basic, applied, and clinical researchers, educators, providers, and journalists-while being very accessible to interested lay readers.

This is the very first book to deal with sex and gender differences in drug therapy - an increasingly recognized medical need. It starts with an overview on S/G in clinical syndromes and a documentation of the medical and socioeconomic damage caused by gender specific adverse drug effects. Part I covers S/G differences in pharmacokinetics. Researchers will be satisfied by the detailed discussion of the mechanisms of S/G differences in drug effects that represents cutting edge science and includes interaction of drugs with sex hormones, genomic and epigenetic mechanisms. It also covers S/G in drug development, in animal models and clinical development and S/G in drug prescriptions. Part II targets S/G differences in drug effects in cardiovascular, pulmonary, CNS, neuromuscular, neuropsychiatric and metabolic diseases, in cancer, inflammation, and rheumatic diseases, in bacterial and retroviral infections, thrombosis, embolism. New drugs will be discussed.

Scientific evidence from both preclinical, and clinical studies indicates that male and female patients with cardiovascular disease (CVD) exhibit different clinical, epidemiological, and pathological characteristics, with sexually dimorphic biological factors exhibiting a significant influence in the development of CVD and therapeutic responses. Sexually dimorphic physiology that contributes to sex differences in cardiovascular therapeutic responses may include; immune responses, cardio-renal health, the blood-brain barrier, coronary atherosclerosis pathology, complications of COVID-19 infections, and the interplay between psychological factors and sedentarism. Furthermore, current knowledge indicates the role of hormonal regulation has a significant impact in sex-specific differences across the clinical cardiology field. The National Institute of Health (NIH) previously adopted a policy to encourage researchers to consider sex as a biological variable (SABV) as well as Sex and Gender Equity in Research (SAGER). In order to promote sexual dimorphic cardiovascular therapeutic development, we have organized this special topic “Sex Differences and Cardiovascular Therapeutics” to provide a scientific forum for cardiovascular scientists and clinicians to present their newest findings in characterizing sex differences in cardiovascular therapeutics. Potential areas of research within this collection may include, but are not limited to: 1) Different outcomes and responses to drug treatment in cardiovascular disease between male and female. 2) Mechanisms of sexual dimorphic response and outcomes related to drug treatment of cardiovascular disease. 3) Sex hormones and their receptors in cardiovascular function in animal studies and clinical therapeutic applications. 4) Gender affirming hormone therapy and cardiovascular function. 5) Regulatory guidance for cardiovascular therapeutics in relation to sex-specific differences.

Cardiac Drugs describes the latest advances in the rapidly evolving area of cardiovascular pharmacology. Written by renowned, USbased experts in cardiology, this book discusses the drug groups for different diseases, such as acute coronary syndromes, hypertension, angina and heart failure. Separate chapters examine cardiac drugs in pregnancy and lactation, and future directions. Enhanced by full colour images and illustrations, this easy to follow text offers practical advice on how to manage cardiac diseases, with a focus on hands-on therapeutic guidance for clinicians.

This book gathers together contributions from internationally renowned authors in the field of cardiovascular systems and provides crucial insight into the importance of sex- and gender-concepts during the analysis of patient data. This innovative title is the first to offer the elements necessary to consider sex-related properties in both clinical and basic studies regarding the heart and circulation on multiscale levels (i.e. molecular, cellular, electrophysiologically, neuroendocrine, immunoregulatory, organ, allometric, and modeling). Observed differences at (ultra)cellular and organ level are quantified, with focus on clinical relevance and implications for diagnosis and patient management. Since the cardiovascular system is of vital importance for all tissues, Sex-Specific Analysis of Cardiovascular Function is an essential source of information for clinicians, biologists, and biomedical investigators. The wide spectrum of differences described in this book will also act as an eye-opener and serve as a handbook for students, teachers, scientists and practitioners.

This book provides a unique contemporary and succinct distillation of the current status of recently delineated electrical diseases of the heart, emphasizing their common and diverse clinical features. The latest developments in the field of experimental and clinical cardiac electrophysiology, genetics, pharmacology and interventional therapies of various clinical arrhythmogenic entities are featured and discussed in terms of recent advances in basic and clinical science. The book is divided into seven major parts. Each part consists of chapters (total of 64) dealing with related topics.